REG - Oxford Biomedica PLC - PDMR Dealings / Market Share sale

Oxford BioMedicaAnnouncement

11/05/2020 16:30

RNS Number : 5399M
  
Oxford Biomedica PLC
  
11 May 2020
  
 

 
 
 
PDMR Dealings / Market Share sale
 
Oxford, UK - 11 May 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 May 2020, that Dr. Jason Slingsby, Chief Business Officer of the Group, exercised options over 2,411 ordinary shares at nil cost and sold all of the resulting shares at 718p. Following this transaction he holds 70,783 options and no shares in the Company.
 
The issued share capital of the Group is 76,983,868 ordinary 50p shares.
 
 
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


Jason Slingsby




2.


Reason for the notification




a)


Position/status


Chief Business Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Exercise of options




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




Nil cost


2,411



 
 




e)


Aggregated information
-    Aggregate volume
 
-    Price
 
-    Aggregated total
 


 
2,411
 
 
Nil cost
 
N/A




f)


Date of the transaction


2020-05-07




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


Jason Slingsby




2.


Reason for the notification




a)


Position/status


Chief Business Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Disposal




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




£7.18


2,411



 
 




e)


Aggregated information
-    Aggregate volume
 
-    Price
 
-    Aggregated total
 


 
2,411
 
 
£7.18
 
£17,310.98




f)


Date of the transaction


2020-05-07




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
-Ends-
 



For further information, please contact:


 




 
Oxford Biomedica plc:
Natalie Walter, Company Secretary


 
Tel: +44 (0)1865 783 000



 
 
About Oxford Biomedica
 
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at www.oxb.com
 
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHSFDFIFESSEEI